Biogen Teams with NeuroSense to Explore ALS Neurofilament Biomarker

Biogen has partnered with NeuroSense Therapeutics to conduct a study on the effects of PrimeC on neurofilament levels in patients with ALS. The study will be funded by Biogen and use blood samples from 69 PARADIGM patients provided by NeuroSense. The collaboration includes data sharing and joint evaluation of correlations among endpoints. PrimeC is an investigational combination therapeutic comp..